apolipoproteins b

Summary

Summary: Structural proteins of chylomicrons, VLDL; and LDL. They are important in the secretion and transport of these LIPOPROTEINS and function as recognition signals for binding and internalization of LDL particles by the LDL receptor (RECEPTORS, LDL). Atherosclerotic patients show high levels of Apo-B in the blood while in the case of ABETALIPOPROTEINEMIA they are not detectable in serum.

Top Publications

  1. ncbi Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications
    Ira Tabas
    Department of Medicine, Columbia University Medical Center, 630 W 168th St, New York, NY 10032, USA
    Circulation 116:1832-44. 2007
  2. ncbi VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
    F M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Circulation 102:1886-92. 2000
  3. ncbi Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
    Tobias Pischon
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Circulation 112:3375-83. 2005
  4. ncbi Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math
    Vimal Ramjee
    J Willis Hurst Internal Medicine Residency, Emory University School of Medicine, Atlanta, GA 30303, USA
    J Am Coll Cardiol 58:457-63. 2011
  5. ncbi Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
  6. ncbi Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
    M Mahmood Hussain
    Department of Anatomy, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    J Lipid Res 44:22-32. 2003
  7. ncbi The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
  8. ncbi The role of the microsomal triglygeride transfer protein in abetalipoproteinemia
    N Berriot-Varoqueaux
    U327 Institut National de la Santé et de la Recherche Médicale, Faculte de Medecine Xavier Bichat, Université de Paris 7 Denis Diderot, 75870 Paris, France
    Annu Rev Nutr 20:663-97. 2000
  9. ncbi Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial
    Rosa Solà
    Human Nutrition Department, School of Medicine, University Rovira i Virgili, Reus, Spain
    Atherosclerosis 218:174-80. 2011
  10. ncbi Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels
    S Marcovina
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Intern Med 259:437-46. 2006

Detail Information

Publications281 found, 100 shown here

  1. ncbi Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications
    Ira Tabas
    Department of Medicine, Columbia University Medical Center, 630 W 168th St, New York, NY 10032, USA
    Circulation 116:1832-44. 2007
    ....
  2. ncbi VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
    F M Sacks
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Circulation 102:1886-92. 2000
    ..Plasma triglyceride concentration has been an inconsistent independent risk factor for coronary heart disease, perhaps because of the metabolic heterogeneity among VLDL particles, the main carriers of triglycerides in plasma...
  3. ncbi Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
    Tobias Pischon
    Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA
    Circulation 112:3375-83. 2005
    ....
  4. ncbi Non-high-density lipoprotein cholesterol versus apolipoprotein B in cardiovascular risk stratification: do the math
    Vimal Ramjee
    J Willis Hurst Internal Medicine Residency, Emory University School of Medicine, Atlanta, GA 30303, USA
    J Am Coll Cardiol 58:457-63. 2011
    ..The purpose of this review is to assess the performance of these parameters in this context and to discuss the considerations of implementation into clinical practice...
  5. ncbi Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy
    G Walldius
    King Gustaf V Research Institute and Karolinska Institute, Stockholm, Sweden
    J Intern Med 255:188-205. 2004
    ..Measurement of these apolipoproteins could improve cardiovascular risk prediction...
  6. ncbi Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly
    M Mahmood Hussain
    Department of Anatomy, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    J Lipid Res 44:22-32. 2003
    ..However, specific steps in lipoprotein assembly that require apoB-MTP binding have not been identified. ApoB-MTP binding may be important for the prevention of degradation and lipidation of nascent apoB...
  7. ncbi The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy--a review of the evidence
    G Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    J Intern Med 259:493-519. 2006
    ..Guidelines should be developed in order to recognize the important clinical risk information embedded in the apoB/apoA-I ratio...
  8. ncbi The role of the microsomal triglygeride transfer protein in abetalipoproteinemia
    N Berriot-Varoqueaux
    U327 Institut National de la Santé et de la Recherche Médicale, Faculte de Medecine Xavier Bichat, Université de Paris 7 Denis Diderot, 75870 Paris, France
    Annu Rev Nutr 20:663-97. 2000
    ..Unless treated, abetalipoproteinemic subjects develop gastrointestinal, neurological, ophthalmological, and hematological abnormalities...
  9. ncbi Effect of a traditional Mediterranean diet on apolipoproteins B, A-I, and their ratio: a randomized, controlled trial
    Rosa Solà
    Human Nutrition Department, School of Medicine, University Rovira i Virgili, Reus, Spain
    Atherosclerosis 218:174-80. 2011
    ..Our aim was to assess the effect of a traditional Mediterranean diet (TMD) on apolipoproteins...
  10. ncbi Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels
    S Marcovina
    Department of Medicine, University of Washington, Seattle, WA, USA
    J Intern Med 259:437-46. 2006
    ..Assessment of apolipoprotein levels is an aid to risk prediction and can be useful in tailoring treatment...
  11. ncbi Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
    John H Contois
    Maine Standards Company, Windham, ME 04062, USA
    Clin Chem 55:407-19. 2009
    ..Low-density lipoprotein cholesterol (LDL-C) has been the cornerstone measurement for assessing cardiovascular risk for nearly 20 years...
  12. ncbi Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon
    S H Chen
    Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030
    Science 238:363-6. 1987
    ..The organ-specific introduction of a stop codon to a mRNA appears unprecedented and might have implications for cryptic polyadenylation signal recognition and RNA processing...
  13. ncbi Human apolipoprotein B: structure of carboxyl-terminal domains, sites of gene expression, and chromosomal localization
    T J Knott
    Science 230:37-43. 1985
    ..The apo-B100 gene is expressed primarily in liver and, to a lesser extent, in small intestine, but in no other tissues. The gene for apo-B100 is located in the p24 region (near the tip of the short arm) of chromosome 2...
  14. pmc Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein
    Richard G Lee
    Cardiovascular Antisense Drug Discovery Group, Isis Pharmaceuticals, Carlsbad, CA 92010, USA
    J Lipid Res 54:602-14. 2013
    ..Thus, although both drugs effectively lowered LDL-C levels in mice, the apoB ASO produced a more positive liver safety profile...
  15. ncbi ACAT2 stimulates cholesteryl ester secretion in apoB-containing lipoproteins
    Ryan E Temel
    Department of Pathology, Section on Lipid Sciences, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Lipid Res 48:1618-27. 2007
    ....
  16. pmc Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk
    Sebastiano Calandra
    Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
    J Lipid Res 52:1885-926. 2011
    ....
  17. pmc Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease
    Brian Spencer
    Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 6:e16575. 2011
    ..Thus, the addition of the ApoB transport domain to the secreted neprilysin generated a non-invasive therapeutic approach that may be a potential treatment in patients with AD...
  18. ncbi High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study
    G Walldius
    Astra Zeneca, Mölndal and King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Lancet 358:2026-33. 2001
    ..We also aimed to establish whether apoB and apoA-I add further information about risk of fatal myocardial infarction to that obtained with total cholesterol, triglycerides, and LDL-cholesterol...
  19. ncbi Cardiac lipid accumulation associated with diastolic dysfunction in obese mice
    Christina Christoffersen
    Departments of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark 2100
    Endocrinology 144:3483-90. 2003
    ..The results also suggest that the cardiac lipid accumulation is paralleled by cardiac diastolic dysfunction in ob/ob mice...
  20. pmc Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
    Daniel J Rader
    Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Clin Invest 111:1795-803. 2003
  21. ncbi Microsomal triglyceride transfer protein promotes the secretion of Xenopus laevis vitellogenin A1
    Jeremy A Sellers
    Department of Pathology, Wake Forest University School of Medicine Winston Salem, North Carolina 27157 1040, USA
    J Biol Chem 280:13902-5. 2005
    ..These studies demonstrate that the biogenesis of Vtg is MTP-dependent and that MTP is the likely ancestral member of the LLTP gene family...
  22. ncbi Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study
    Christa Meisinger
    Central Hospital of Augsburg, MONICA KORA Myocardial Infarction Registry, Augsburg, Germany
    Eur Heart J 26:271-8. 2005
    ..To investigate the association between apolipoprotein B (apoB), A-I (apoA-I), the apoB/apoA-I ratio, and the incidence of coronary events...
  23. ncbi Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study
    B H R Wolffenbuttel
    University Medical Centre, Groningen, The Netherlands
    J Intern Med 257:531-9. 2005
    ..To compare the efficacy of the newest cholesterol-lowering drug, rosuvastatin (RSV) with atorvastatin (ATV) in subjects with type 2 diabetes...
  24. ncbi Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid
    Ernst Malle
    Medical University Graz, Center of Molecular Medicine, Institute of Molecular Biology and Biochemistry, Harrachgasse 21, A 8010 Graz, Austria
    Biochim Biophys Acta 1761:392-415. 2006
    ....
  25. pmc Adiponectin reduces plasma triglyceride by increasing VLDL triglyceride catabolism
    Liping Qiao
    Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, Kentucky, USA
    Diabetes 57:1824-33. 2008
    ..The main aims of this study are to investigate the effects of adiponectin on VLDL triglyceride (VLDL-TG) metabolism and the underlying mechanism...
  26. ncbi Leukocyte activation by triglyceride-rich lipoproteins
    Arash Alipour
    Department of Internal Medicine, University Medical Center Utrecht, The Netherlands
    Arterioscler Thromb Vasc Biol 28:792-7. 2008
    ..Postprandial lipemia has been linked to atherosclerosis and inflammation. Because leukocyte activation is obligatory for atherogenesis, leukocyte activation by triglyceride-rich lipoproteins (TRLs) was investigated...
  27. ncbi Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy
    Fatima Akdim
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Am Coll Cardiol 55:1611-8. 2010
    ..The aim of this study was to evaluate the efficacy and safety of mipomersen in hypercholesterolemic subjects taking stable statin therapy...
  28. ncbi Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study
    Sonia S Anand
    Population Health Research Institute, Hamilton Health Sciences, Ontario, Canada
    Circ Cardiovasc Genet 2:16-25. 2009
    ..Myocardial infarction (MI) is a leading cause of death globally, but specific genetic variants that influence MI and MI risk factors have not been assessed on a global basis...
  29. ncbi Apolipoprotein measurements: is more widespread use clinically indicated?
    Michael H Davidson
    Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA
    Clin Cardiol 32:482-6. 2009
    ....
  30. ncbi Overexpression of apolipoprotein B in the heart impedes cardiac triglyceride accumulation and development of cardiac dysfunction in diabetic mice
    Lars Bo Nielsen
    Department of Clinical Biochemistry KB3011, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK 2100 Copenhagen, Denmark
    J Biol Chem 277:27014-20. 2002
    ..The findings suggest that triglyceride accumulation in the heart is important for development of diabetic cardiomyopathy in mice, and that lipoprotein formation by cardiomyocytes plays an integrated role in cardiac lipid metabolism...
  31. ncbi Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP
    L J Wilcox
    Departments of Medicine and Biochemistry and The John P. Robarts Research Institute, 4-16, University of Western Ontario, 100 Perth Drive, London, Ontario N6A 5K8, Canada
    J Lipid Res 42:725-34. 2001
    ..Together with an enhanced expression of the LDL receptor, these mechanisms may explain the hypocholesterolemic properties of the citrus flavonoids...
  32. ncbi Structure of apolipoprotein B-100 in low density lipoproteins
    J P Segrest
    Department of Medicine, 630 Boshell Bldg, 3, UAB Medical Center, Birmingham, AL 35294 0012, USA
    J Lipid Res 42:1346-67. 2001
    ....
  33. ncbi Molecular diagnosis of hypobetalipoproteinemia: an ENID review
    Patrizia Tarugi
    Department of Biomedical Sciences, University of Modena e Reggio Emilia, Via Campi 287, I 41100 Modena, Italy
    Atherosclerosis 195:e19-27. 2007
    ..Inactivation of this enzyme is associated with an increased LDL uptake and hypobetalipoproteinemia. HBL carriers of PCSK9 mutations do not develop fatty liver disease...
  34. pmc Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100
    J Boren
    Gladstone Institute of Cardiovascular Disease, University of California, San Francisco, California 94141 9100, USA
    J Clin Invest 101:1084-93. 1998
    ..Moreover, the loss of arginine at this site destabilizes this interaction, resulting in receptor-binding defective LDL...
  35. pmc Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
    S E Humphries
    J Med Genet 43:943-9. 2006
    ..Patients and..
  36. ncbi Clinical utility of different lipid measures for prediction of coronary heart disease in men and women
    Erik Ingelsson
    Framingham Heart Study, 73 Mount Wayte Ave, Suite 2, Framingham, MA 01702 5803
    JAMA 298:776-85. 2007
    ..Evidence is conflicting regarding the performance of apolipoproteins vs traditional lipids for predicting coronary heart disease (CHD) risk...
  37. ncbi Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation
    Joerg Heeren
    Institute for Biochemistry and Molecular Biology II Molecular Cell Biology and Department of Internal Medicine, University Hospital Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    J Biol Chem 279:55483-92. 2004
    ..These studies provide initial evidence that impaired recycling of apoE4 could interfere with intracellular cholesterol transport and contribute to the pathophysiological lipoprotein profile observed in apoE4 homozygotes...
  38. ncbi Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Dr, Lobby A, Ann Arbor, MI 48106 0736, USA
    Diabetes Care 30:1945-51. 2007
    ..The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome...
  39. ncbi Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Montreal, Quebec, Canada
    Am J Cardiol 91:1173-7. 2003
    ....
  40. pmc Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
    Hua Huang
    Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390 9046, USA
    Proc Natl Acad Sci U S A 104:5848-53. 2007
    ..These results provide a possible explanation for the restriction of HCV production to the liver and suggest new cellular targets for treatment of HCV infection...
  41. pmc Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion
    Pablo Gastaminza
    The Scripps Research Institute, Maildrop SBR 10, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 82:2120-9. 2008
    ..These results suggest that by coopting the VLDL assembly, maturation, degradation, and secretory machinery of the cell, HCV acquires its hepatocyte tropism and, by mimicry, its tendency to persist...
  42. pmc Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice
    Adam E Mullick
    Isis Pharmaceuticals, Inc, Carlsbad, CA, USA
    J Lipid Res 52:885-96. 2011
    ....
  43. ncbi Variants of the microsomal triglyceride transfer protein gene are associated with plasma cholesterol levels and body mass index
    Helena Ledmyr
    King Gustaf V Research Institute, Karolinska Hospital, SE 171 76, Stockholm, Sweden
    J Lipid Res 43:51-8. 2002
    ..This may, in turn, have implications for genetic regulation of cardiovascular risk factors...
  44. ncbi Diurnal triglyceride profiles: a novel approach to study triglyceride changes
    M Castro Cabezas
    Department of Internal Medicine and Endocrinology, F02.124, University Hospital Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands
    Atherosclerosis 155:219-28. 2001
    ..Diurnal capillary TG profiles may be used to estimate the total daily load of potential atherogenic particles to which individuals are subjected during the day without the need for metabolic ward studies...
  45. pmc Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100
    R V Farese
    Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94141 9100, USA
    Proc Natl Acad Sci U S A 93:6393-8. 1996
    ..The apo-B48-only and apo-B100-only mice should prove to be valuable models for experiments designed to understand the purpose for the two forms of apo-B in mammalian metabolism...
  46. ncbi Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study
    A R Sharrett
    Epidemiology and Biometry Program, National Heart, Lung, and Blood Institute, Bethesda, MD, USA
    Circulation 104:1108-13. 2001
    ..CONCLUSIONS: Optimal LDL-C values are <100 mg/dL in both women and men. LDL-C, HDL-C, TG, and Lp(a), without additional apolipoproteins or lipid subfractions, provide substantial CHD prediction, with much higher RR in women than men...
  47. ncbi RNAi-mediated gene silencing in non-human primates
    Tracy S Zimmermann
    Alnylam Pharmaceuticals Inc, 300 Third Street, Cambridge, Massachusetts 02142, USA
    Nature 441:111-4. 2006
    ..Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs...
  48. ncbi Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study
    I Lemieux
    Quebec Heart Institute, Laval Hospital Research Center, 2725, chemin Sainte-Foy, Sainte-Foy, Quebec G1V 4G5, Canada
    Arch Intern Med 161:2685-92. 2001
    ....
  49. ncbi The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins
    Anna Lena Berg
    Department of Nephrology, University Hospital, Lund 221 85, Sweden
    Metabolism 55:1083-7. 2006
    ..These, in combination with previous in vitro results, indicated an ACTH-specific effect...
  50. ncbi Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells
    Jun shan Liang
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Biol Chem 278:23984-8. 2003
    ..Together, these results indicate that an ER-associated protein, gp78, is a bona fide E3 ligase in the apoB ER-associated degradation pathway...
  51. pmc Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition
    Jahangir Iqbal
    Department of Anatomy and Cell Biology and Pediatrics, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    J Biol Chem 283:19967-80. 2008
    ..We speculate that non-lipoprotein-producing cells may use different mechanisms to alleviate product inhibition and modulate cholesteryl ester biosynthesis...
  52. pmc Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids
    Muhammad Bayu Sasongko
    Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, Australia
    Diabetes Care 34:474-9. 2011
    ..To describe and compare the associations of serum lipoproteins and apolipoproteins with diabetic retinopathy...
  53. ncbi The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins
    C J Mann
    MRC Molecular Medicine Group, Imperial College School of Medicine, London W12 ONN, UK
    J Mol Biol 285:391-408. 1999
    ..The structural and functional evolution of the VTGs provides a unifying scheme for the invertebrate origins of the major vertebrate lipid transport system...
  54. ncbi Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing li
    Mehran Haidari
    Department of Laboratory Medicine and Pathobiology, Hospital for Sick Children, University of Toronto, Toronto, Ontario M5G 1X8, Canada
    J Biol Chem 277:31646-55. 2002
    ....
  55. ncbi Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
    A D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, QC, Canada
    Lancet 361:777-80. 2003
  56. ncbi Effects of oxidation on the structure and stability of human low-density lipoprotein
    Shobini Jayaraman
    Department of Physiology and Biophysics, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Biochemistry 46:5790-7. 2007
    ....
  57. ncbi Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice
    Xinjie Lu
    Thrombosis Research Institute, London, United Kingdom
    Atherosclerosis 212:472-80. 2010
    ....
  58. ncbi Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes
    Francine K Welty
    Lipid Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center at Tufts University, 711 Washington St, Boston, MA 02111, USA
    Arterioscler Thromb Vasc Biol 24:1703-7. 2004
    ..Our purpose was to determine the relationship between apolipoprotein (apo) A-I and apoB-48 and apoB-100 metabolism in moderately hypercholesterolemic humans...
  59. ncbi Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
    Jürgen Soutschek
    Alnylam Europe AG, Fritz Hornschuch Str 9, 95326 Kulmbach, Germany
    Nature 432:173-8. 2004
    ..These findings demonstrate the therapeutic potential of siRNAs for the treatment of disease...
  60. ncbi Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease
    Yusuke Uemura
    Department of Cardiology, Cardiovascular Center, Anjo Kosei Hospital, Anjo, Japan
    J Cardiol 59:50-6. 2012
    ..Changes in serum lipids, including malondialdehyde-modified LDL (MDA-LDL) as a representative form of oxidized LDL cholesterol, and glucose metabolism were assessed...
  61. pmc An immune response network associated with blood lipid levels
    Michael Inouye
    Department of Human Genetics, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, United Kingdom
    PLoS Genet 6:e1001113. 2010
    ....
  62. ncbi Structural biology. LDL receptor's beta-propeller displaces LDL
    Thomas L Innerarity
    Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94110, USA
    Science 298:2337-9. 2002
  63. pmc The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms
    C Cladaras
    EMBO J 5:3495-507. 1986
    ..These two messages may have resulted from differential splicing of the same primary apoB mRNA transcript...
  64. ncbi Effect of the microsomal triglyceride transfer protein -493 G/T polymorphism and type 2 diabetes mellitus on LDL subfractions
    S P L Chen
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam Road, Hong Kong
    Atherosclerosis 167:287-92. 2003
    ..01). In conclusion, the -493 G/T polymorphism only has a minor effect on LDL subfraction pattern in Chinese and the effect is only apparent in the presence of type 2 diabetes...
  65. ncbi The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
    Goran Walldius
    King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden
    Clin Chem Lab Med 42:1355-63. 2004
    ..Moreover, we examined whether any lipids, lipoproteins or cholesterol ratios add significant predictive information beyond that provided by the apoB/apoA-I ratio...
  66. ncbi A Drosophila microsomal triglyceride transfer protein homolog promotes the assembly and secretion of human apolipoprotein B. Implications for human and insect transport and metabolism
    Jeremy A Sellers
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1040, USA
    J Biol Chem 278:20367-73. 2003
    ..We conclude that CG9342 and human MTP are orthologs that share only a subset of functions, consistent with known differences in intracellular and extracellular aspects of vertebrate and invertebrate lipid transport and metabolism...
  67. ncbi Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)
    Ken Williams
    Department of Medicine, University of Texas Health Science Center, San Antonio, USA
    Circulation 108:2312-6. 2003
    ..This study compares the associations of apolipoprotein B (apoB) and LDL cholesterol (LDLC) with a wide array of measures of these risk factors...
  68. ncbi Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100
    S Stefansson
    Biochemistry Department, J H Holland Laboratory, American Red Cross, Rockville, Maryland 20855, USA
    J Biol Chem 270:19417-21. 1995
    ..The results indicate that LRP-2 can function to mediate cellular endocytosis of LDL, leading to its degradation. LRP-2 represents the second member of the LDLR family identified as functioning in the catabolism of LDL...
  69. ncbi Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution
    Khemanganee E Liyanage
    School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia
    Crit Rev Clin Lab Sci 48:1-18. 2011
    ....
  70. ncbi Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is
    Allan D Sniderman
    Circulation 112:3366-7. 2005
  71. ncbi Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
    M R Taskinen
    Department of Medicine, Division of Cardiology, Helsinki University Central Hospital, Biomedicum, Haartmaninkatu 8, Helsinki, Finland
    Diabetologia 53:1846-55. 2010
    ....
  72. ncbi Phospholipid transfer activity of microsomal triacylglycerol transfer protein is sufficient for the assembly and secretion of apolipoprotein B lipoproteins
    Paul Rava
    Department of Anatomy and Cell Biology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    J Biol Chem 281:11019-27. 2006
    ..Identification of MTP inhibitors, which selectively affect transfer of a specific lipid class, may have therapeutic potential...
  73. ncbi Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein
    P J W H Kappelle
    Departments of Endocrinology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    J Intern Med 269:232-42. 2011
    ..We compared the strength of these ratios with first MACE in the general population and determined whether these associations remain when taking account of these risk markers...
  74. ncbi Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk
    S Holewijn
    Division of Vascular Medicine, Department of General Internal Medicine, Radboud University, Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Intern Med 268:567-77. 2010
    ....
  75. ncbi Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men
    Dick C Chan
    School of Medicine and Pharmacology, University of Western Australia, Royal Perth Hospital, Perth, Western Australia 6847, Australia
    J Clin Endocrinol Metab 94:989-97. 2009
    ..The mechanisms regulating apoA-I catabolism may relate to alterations in very low density lipoprotein (VLDL) metabolism and plasma adiponectin and serum amyloid A protein (SAA) concentrations...
  76. pmc Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia
    Maartje E Visser
    Department of Vascular Medicine, Academic Medical Center Amsterdam, The Netherlands
    J Lipid Res 51:1057-62. 2010
    ..Future studies evaluating the effects of long-term use of mipomersen reaching more profound reductions in apoB are required prior to broader use of this compound...
  77. ncbi Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
    Allan Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Center, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, QC H3A 1A1, Canada
    Nat Rev Endocrinol 6:335-46. 2010
    ..Here, we review the diagnostic algorithm for apoB dyslipoproteinemias and provide, for the first time, a treatment plan on the basis of a reduction of atherogenic lipoprotein particles rather than plasma lipids...
  78. ncbi Phenotypic expression of familial hypobetalipoproteinemia in three kindreds with mutations of apolipoprotein B gene
    P Tarugi
    Dipartimento di Scienze Biomediche, Universita di Modena e Reggio Emilia, Via Campi 287, I 41100 Modena, Italy
    J Lipid Res 42:1552-61. 2001
    ....
  79. ncbi When is equal not equal?
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Room H7 22, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    J Clin Lipidol 4:83-8. 2010
    ..Our objective should be to learn how to combine the information from parameters rather than eliminate them and we need to focus on evaluation of risk in individuals and not just groups...
  80. ncbi APOLIPOPROTEIN B: mRNA editing, lipoprotein assembly, and presecretory degradation
    N O Davidson
    Departments of Medicine and Molecular Biology and Pharmacology, Washington University Medical School, St Louis, Missouri 63110, USA
    Annu Rev Nutr 20:169-93. 2000
    ..Although control of lipid secretion in vivo is primarily achieved at the level of lipoprotein particle size, regulation of apoB production by presecretory degradation may be relevant in some dyslipidemic states...
  81. ncbi Comparison of apolipoprotein B metabolism in familial defective apolipoprotein B and heterogeneous familial hypercholesterolemia
    Dairena Gaffney
    Department of Pathological Biochemistry, Glasgow Royal Infirmary, North Glasgow Hospitals University NHS Trust, 4th Floor, Queen Elizabeth Building, Alexandra Parade, Glasgow G31 2ER, Scotland, UK
    Atherosclerosis 162:33-43. 2002
    ..We conclude that disturbances in IDL metabolism provide the basis for understanding why FDB is less severe than FH. Our findings suggest that an apoB-LDL receptor interaction is important in the IDL to LDL conversion...
  82. ncbi The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III
    Sung Koo Kang
    National Research Laboratory for Glycobiology, and Department of Biochemistry and Molecular Biology, College of Oriental Medicine, Dongguk University, Sukjang dong 707, Kyungju City, Kyungbuk 780 714, Korea
    J Biol Chem 279:28106-12. 2004
    ....
  83. ncbi Hepatic fatty acid synthesis is suppressed in mice with fatty livers due to targeted apolipoprotein B38.9 mutation
    Xiaobo Lin
    Division of Atherosclerosis, Nutrition and Lipid Research, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
    Arterioscler Thromb Vasc Biol 22:476-82. 2002
    ..The signals mediating suppression of FAS and SREBP-1c levels remain to be identified...
  84. ncbi Management of non-high-density lipoprotein abnormalities
    Robert S Rosenson
    Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, State University of New York, Downstate, Brooklyn, NY, USA
    Atherosclerosis 207:328-35. 2009
    ..Improvement in lipid control and reduction in atherogenic risk could be anticipated to translate to benefits in clinical outcomes...
  85. ncbi Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?
    Saman Miremadi
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, V6Z 1Y6, Canada
    Clin Chem 48:484-8. 2002
    ..Considerable evidence indicates that apolipoprotein B (apo B) is a better index of reaching or not reaching treatment targets than total or LDL cholesterol...
  86. ncbi Nascent lipidated apolipoprotein B is transported to the Golgi as an incompletely folded intermediate as probed by its association with network of endoplasmic reticulum molecular chaperones, GRP94, ERp72, BiP, calreticulin, and cyclophilin B
    Jianying Zhang
    Department of Physiology and Biophysics, Center for Advanced Biomedical Research, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Biol Chem 278:7459-68. 2003
    ....
  87. ncbi Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia
    Delphine Allard
    INSERM UR383, Hopital Necker Enfants Malades
    Hum Mutat 26:497. 2005
    ..3%) and that additional environmental or genetic factors may contribute to the phenotype caused by PCSK9 missense mutations in humans...
  88. ncbi Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9
    Khadija Ouguerram
    INSERM U 539, Centre de Recherche en Nutrition Humaine de Nantes, France
    Arterioscler Thromb Vasc Biol 24:1448-53. 2004
    ..Our aim was to define the metabolic bases of this new form of hypercholesterolemia...
  89. ncbi Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome
    Justo Sierra-Johnson
    Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, USA
    Am J Cardiol 98:1369-73. 2006
    ..An elevated apo-B/apo-AI ratio may constitute an important feature of the metabolic syndrome and may provide an additional mechanism to explain the increased cardiovascular risk in subjects with this syndrome...
  90. ncbi Polymorphisms at cholesterol 7alpha-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease
    Zhao Yan Jiang
    Department of Surgery, Ruijin Hospital, Shanghai Second Medical University, Shanghai 200025, China
    World J Gastroenterol 10:1508-12. 2004
    ....
  91. pmc Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients
    Søren U Nielsen
    Liver Research Group, School of Clinical Medical Sciences, University of Newcastle, England
    J Virol 80:2418-28. 2006
    ..Immunoprecipitation analysis showed that ApoB remained associated with HCV after treatment of serum with deoxycholic acid or NP-40, whereas ApoE was removed from HCV with these detergents...
  92. ncbi Microsomal triglyceride transfer protein, the abetalipoproteinemia gene product, mediates the secretion of apolipoprotein B-containing lipoproteins from heterologous cells
    J M Leiper
    Medical Research Council Molecular Medicine Group, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom
    J Biol Chem 269:21951-4. 1994
    ....
  93. ncbi 2000 George Lyman Duff Memorial Lecture: atherosclerosis is a liver disease of the heart
    R A Davis
    Mammalian Cell and Molecular Biology Laboratory, San Diego State University, San Diego, CA 92182 4614, USA
    Arterioscler Thromb Vasc Biol 21:887-98. 2001
    ..Oxysterols and bile acids may also act via the ligand-activated nuclear receptors LXR and FXR to link the metabolic pathways controlling energy balance and lipid metabolism to nutritional state...
  94. ncbi Carotid intima-media thickness and apolipoprotein B/apolipoprotein A-I ratio in middle-aged patients with Type 2 diabetes
    E M Dahlén
    Department of Medical and Health Sciences, Linkoping University, Linkoping, Sweden
    Diabet Med 26:384-90. 2009
    ..To explore the association between carotid intima-media thickness (IMT) and the apolipoprotein B (apoB)/apolipoprotein A-I (apoA-I) ratio compared with conventional lipids in middle-aged patients with Type 2 diabetes...
  95. ncbi Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
    Kristina Skålén
    Wallenberg Laboratory for Cardiovascular Research, Goteborg University, Göteborg S 4345, Sweden
    Nature 417:750-4. 2002
    ..We conclude that subendothelial retention of apoB100-containing lipoprotein is an early step in atherogenesis...
  96. ncbi Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project
    A Taylor
    Great Ormond Street Hospital for Children, London, UK
    Clin Genet 77:572-80. 2010
    ..Even in subjects with a low clinical suspicion of FH, and in those of Indian origin, mutation testing has an acceptable detection rate...
  97. ncbi Overproduction of large VLDL particles is driven by increased liver fat content in man
    M Adiels
    Wallenberg Laboratory, Gothenburg University, Gothenburg, Sweden
    Diabetologia 49:755-65. 2006
    ..We determined whether hepatic fat content and plasma adiponectin concentration regulate VLDL(1) production...
  98. ncbi Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2
    Carey J Ng
    Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    J Biol Chem 281:29491-500. 2006
    ..These results demonstrate that PON2 plays a protective role in atherosclerosis...
  99. pmc Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B
    Shumei Zhong
    Department of Biochemistry, Microbiology and Immunology, Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, Ontario K1H 8M5, Canada
    J Biol Chem 285:6453-64. 2010
    ..These results suggest that feedback inhibition of hepatic lipogenesis in conjunction with post-ER degradation of misfolded apoB proteins can contribute to reduce fat accumulation in the FHBL liver...
  100. pmc New approaches to target microsomal triglyceride transfer protein
    Mohammed Mahmood Hussain
    Departments of Anatomy and Cell Biology, and Pediatrics, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    Curr Opin Lipidol 19:572-8. 2008
    ..MTP inhibition increases plasma transaminases and tissue lipids, and therefore new approaches are needed to avoid them...
  101. ncbi Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
    Clin Biochem 36:499-504. 2003

Research Grants67

  1. Comprehensive biomarker study to capitalize on existing GWAS in 10K South Asians
    Danish Saleheen; Fiscal Year: 2010
    ..We seek support for additional blood markers to PROMIS by assaying plasma biomarkers potentially relevant to atherogenesis, plaque rupture and/or thrombosis. ..
  2. Thyroid Hormone Action
    THOMAS STERLING SCANLAN; Fiscal Year: 2013
    ....
  3. Chemical Biology Studies of 3-Iodothyronamine and Related Thyroid Hormone Metabol
    THOMAS STERLING SCANLAN; Fiscal Year: 2013
    ..4) Determine the mechanism of intracellular uptake of T1AM and search for T1AM target proteins. ..
  4. Lipid Metabolism and Steatosis in Liver
    Amrita Kamat; Fiscal Year: 2013
    ..The study is expected to have an important impact by defining new molecular targets for the prevention and/or treatment of NAFLD and its complications. ..
  5. Lipoprotein Structure and Function by Individual Particle Electron Tomography
    Gang Ren; Fiscal Year: 2013
    ....
  6. Avoiding toxicity associated with MTP ablation
    M Mahmood Hussain; Fiscal Year: 2013
    ..Proposed studies may lead to new therapeutic modalities for the treatment of various disorders associated with high plasma lipids. ..
  7. Development of CNS-targeted AAV vectors
    MIGUEL S ESTEVES; Fiscal Year: 2012
    ..of CNS-targeted AAV vectors to foster the development of highly effective gene therapy approaches to treat many childhood, adult, and geriatric neurological diseases currently beyond the reach of modern medicine ..
  8. Targets of a cytidine deaminase required for left-right axis in Xenopus
    Alin Vonica; Fiscal Year: 2010
    ..Finding the genes targeted by APOBEC2 will significantly improve our knowledge of a family of proteins increasingly important in human pathology. ..
  9. Regulation of Leukocyte Migration by Plasminogen
    JANE LEE HOOVER-PLOW; Fiscal Year: 2013
    ..The objective of this proposal is to determine the mechanisms by which plasminogen regulates cell migration and, thereby, the inflammatory responses that contribute to thrombosis and CVD. ..
  10. The altered lipid and protein metabolism of pediatric patients with HIV infection
    Farook Jahoor; Fiscal Year: 2010
    ..Knowledge gained from this project may lead to new nutritional therapies to help prevent these conditions. ..
  11. Outcomes and Predictors in Mild Cognitive Impairment
    Mary Ganguli; Fiscal Year: 2012
    ..The Awardee will also continue to organize trainee workshops in neglected areas such as project management, principles of neuropsvcholoav for non-psvcholoaists. and scientific writing skills. ..
  12. Serum amyloid P and chronic noncommunicable diseases
    Weibin Shi; Fiscal Year: 2010
    ..The proposed research offers an opportunity to assess the contribution of serum amyloid P to the development of chronic noncommunicable diseases. ..
  13. iPS-derived hepatocytes as a model of familial hypercholesterolemia
    Max A Cayo; Fiscal Year: 2013
    ..abstract_text> ..
  14. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS
    NICHOLAS DAVIDSON; Fiscal Year: 2013
    ....
  15. Discovery of Mendelian Dyslipidemia and Heart Attack Genes Using Exome Sequencing
    Sekar Kathiresan; Fiscal Year: 2013
    ..After identifying the causal genes in families, we will test whether these genes influence risk for heart attack in the general population. ..
  16. Molecular Basis of Autosomal Dominant Hypercholesterolemia in a Multiethnic Cohor
    Zahid Ahmad; Fiscal Year: 2013
    ..The studies outlined in this project will provide the basis for the development of new therapeutic options for the prevention of this potentially life-threatening chronic disease. ..
  17. Stem Cell Models of Familial Combined Hypolipidemia
    Kiran Musunuru; Fiscal Year: 2013
    ..If successful, our approach of using genome-edited, hPSC-derived cells to study the effects of disease-associated mutations could be applied widely to a large variety of human genetic disorders. ..
  18. MOLECULAR REGULATION OF APOPROTEIN B DEGRADATION
    Edward A Fisher; Fiscal Year: 2012
    ..abstract_text> ..
  19. Screens for novel compounds to correct diabetic postprandial dyslipidemia
    Kevin Jon Williams; Fiscal Year: 2011
    ..The ultimate goal will be to avert the tremendous excess burden of cardiovascular disease in diabetes. ..
  20. Fatty acid sources of fructose and HFCS-induced postprandial hypertriglyceridemia
    Jean Marc Schwarz; Fiscal Year: 2013
    ..A second objective is to determine the doses of HFCS that increase the absolute and proportional contributions of DNL-fatty acids to postprandial TRL. ..
  21. Markers of the metabolic syndrome linking type 2 diabetes and MI in South Asia
    Danish Saleheen; Fiscal Year: 2010
    ....
  22. Assembly and Secretion of ApoB Containing Lipoproteins
    Henry N Ginsberg; Fiscal Year: 2013
    ..The detailed and broad-based studies of autophagy and apoB proposed herein could provide new approaches to reducing VLDL secretion while avoiding hepatic steatosis. ..
  23. Effects of amino acids on regional lipid metabolism
    Elisabet Borsheim; Fiscal Year: 2013
    ..The overall goal of this project is to test a novel treatment using nutrient (amino acid) supplementation against this condition in men and women, and to understand how this treatment works. ..
  24. Structure Function Relationship of Human Apolipoprotein B100
    Nassrin Dashti; Fiscal Year: 2013
    ..abstract_text> ..
  25. Hepatic Rictor Knockout Mouse Model and the Metabolic Syndrome
    JENNIFER MARIE ROJAS; Fiscal Year: 2012
    ..The possibility of hepatic steatosis will be assessed by liver lipid quantification. ..
  26. Dyslipidemia, Lipoic Acid and Diabetic Vascular Complications in Humanized
    Nobuyo Maeda; Fiscal Year: 2010
    ....
  27. Apolipoprotein B and Control of S. aureus Quorum Sensing
    PAMELA RANEL HALL; Fiscal Year: 2013
    ..abstract_text> ..
  28. STRUCTURE AND FUNCTION OF APOLIPOPROTEIN A-IV
    Richard B Weinberg; Fiscal Year: 2010
    ..We believe that these studies will provide new knowledge on the function of apo A-IV in the complex process of lipoprotein assembly relevant to the dietary control of atherosclerotic cardiovascular disease and obesity. ..
  29. Regulation of plasma lipids and atherosclerosis by miR-30c
    M Mahmood Hussain; Fiscal Year: 2013
    ..If proven, miR-30c might serve as a potentially new therapeutic agent to treat hyperlipidemia, atherosclerosis and other related metabolic disorders. ..
  30. A Cell Biological Approach to Hepatic Lipid Metabolism
    Shadab A Siddiqi; Fiscal Year: 2012
    ..The identification of proteins involved in the process of VLDL selection into VTVs, VTV budding and its fusion with Golgi would offer potential targets for their inhibition and thus potentially to control VLDL secretion from the liver. ..
  31. ENZYMATIC REACTIONS OF PLASMA LIPOPROTEINS
    Henry J Pownall; Fiscal Year: 2010
    ....
  32. New Avenues in GPIHBP1 Research
    Anne Beigneux; Fiscal Year: 2012
    ..abstract_text> ..
  33. Saturated Fat and Protein Effects on Atherogenic Dyslipidemia
    Ronald M Krauss; Fiscal Year: 2013
    ....
  34. Viral Hepatitis C and Lipid Homeostasis
    Aleem Siddiqui; Fiscal Year: 2012
    ....
  35. Zebrafish models of vascular inflammation and atherosclerosis
    Yury Miller; Fiscal Year: 2013
    ....
  36. HSPGs as remnant receptors: critical role in diabetic postprandial dyslipidemia
    Kevin Jon Williams; Fiscal Year: 2012
    ..The work will expand our understanding of excess cardiovascular disease in diabetes and provide novel therapeutic targets. ..
  37. Mechanisms of PAI-1 Induced Anti-Angiogenesis
    Mary J Mulligan Kehoe; Fiscal Year: 2011
    ....
  38. Premature Aging, Vascular Disease and Endothelial Mechanotransduction
    WILLIAM JAMES ADAMS; Fiscal Year: 2012
    ..This will indicate whether the premature aging model endothelium is predisposed atherosclerosis due to dysfunctional mechanotransduction. ..
  39. Mechanisms of Defective Efferocytosis in Atherosclerosis
    IRA A TABAS; Fiscal Year: 2013
    ..Achieving the stated objective will provide critical information for understanding how necrotic cores form and may help in the design of new therapeutic strategies to prevent the clinical progression of atherosclerotic lesions. ..
  40. Proteostasis Network Factors Involved in Apolipoprotein B Folding and Secretion
    Joseph Genereux; Fiscal Year: 2012
    ..We will identify the factors of the proteostasis network that regulate apoB folding and processing into VLDL, and characterize the impact of these factors on VLDL secretion. ..
  41. Hyperinsulinemia, mTOR activity and plasma lipoproteins
    ALAN RICHARD TALL; Fiscal Year: 2012
    ..However, the underlying mechanisms have remained poorly understood. The proposed studies should provide new insights into the regulation of VLDL secretion and LDLR levels in these conditions. ..
  42. Pathways of fenofibrate effects on cardiovascular outcomes in ACCORD
    Henry N Ginsberg; Fiscal Year: 2013
    ..women, Whites vs non-whites, and dyslipidemics vs non-dyslipidemics. ..
  43. Characterization of microRNA-lipid-HCV interactions
    ESPERANCE ANNE KREEK SCHAEFER; Fiscal Year: 2013
    ..Taken together, these studies will serve to clarify the relationship between microRNA-122, HCV, and lipid metabolism and provide insights into the pathogenesis of chronic hepatitis and its related derangements, including steatosis. ..
  44. Circadian regulation of lipid metabolism
    M Mahmood Hussain; Fiscal Year: 2013
    ..The outcomes from these studies will impact two fields of biology;lipid metabolism and circadian regulation. Novel understanding about the circadian regulation of lipid metabolism will be garnered. ..
  45. Interrogation of novel pathways regulating VLDL production and plasma lipids
    DANIEL JAMES RADER; Fiscal Year: 2013
    ....
  46. Nutritional and Hormonal Pathways for Reduction of ApoB-lipoproteins
    Li Shin Huang; Fiscal Year: 2013
    ....
  47. MOLECULAR MECHANISMS OF OXIDATION OF LDL
    Sampath Parthasarathy; Fiscal Year: 1999
    ..He also proposes to generate antibodies against specific dicarboxylic acid containing phospholipids. He will then determine whether such antibodies react against epitopes in oxidized LDL, plasma and atherosclerotic plaques. ..
  48. Lipogenesis, lipoprotein flux &CVD risk: role of meal composition &frequency
    Jean Marc Schwarz; Fiscal Year: 2013
    ..These findings could inform efforts to develop evidence-based interventions and dietary guidance to mitigate CVD risk. ..
  49. Endothelial Dysfunction, Oxidative Stress and Risk of Peripheral Arterial Disease
    Kenneth Jay Mukamal; Fiscal Year: 2010
    ..Finally, we will examine how a derived dietary antioxidant score, based upon measured oxidative potential of specific foods using the ferric-reducing/antioxidant power method, is related to PAD. ..
  50. APOLIPOPROTEIN B48 AND LIPOPROTEIN METABOLISM
    Lawrence Chan; Fiscal Year: 2004
    ..Thus, the overall project is highly relevant to lipid nutrient absorption and homeostasis. Significantly, it also provides important information on a newly described pathway in posttranscriptional gene regulation. ..
  51. NUTRITIONAL EFFECTS OF SUGARS ON LIVER LIPIDS
    CHARLES SPARKS; Fiscal Year: 1990
    ..Studies are important considering apo B and apo A-I lipoproteins are risk factors in atherogenesis...
  52. ASSEMBLY OF NASCENT PLASMA LIPOPROTEINS BY HEPATOCYTES
    Robert Hamilton; Fiscal Year: 1991
    ..Answers to these basic questions may indicate ways in which VLDL assembly and secretion can be regulated as a means of controlling the levels of atherogenic and antiatherogenic lipoproteins...
  53. ApoB and ApoA-I Kinetics in the ApoB-67 Mutation
    Francine Welty; Fiscal Year: 2006
    ..The apoB-67 mutation may provide insights into mechanisms of low LDL-C and high HDL-C levels and new and better therapies to lower cholesterol. ..
  54. REGULATION OF APOB SECRETION IN INBRED MOUSE STRAINS
    Li Shin Huang; Fiscal Year: 2009
    ..It will also be a potential target for drug discovery and pharmacological intervention in hyperlipidemic patients in the general population. ..
  55. AMPHIPATHIC MOTIFS, LIPOPROTEINS AND ATHEROSCLEROSIS
    Jere P Segrest; Fiscal Year: 2012
    ..Dashti). The proposed studies will contribute to the prevention and reversal of coronary heart disease through information leading to the development of better pharmaceutical agents. ..
  56. EDITING OF APOLIPOPROTEIN-B MRNA
    DONNA DRISCOLL; Fiscal Year: 2004
    ..The successful pursuit of these aims should provide insight into the mechanism of apo-B mRNA editing and the function of ACF. ..
  57. MECHANISM OF APOLIPOPROTEIN B-48 BIOGENESIS
    Lawrence Chan; Fiscal Year: 1993
    ..The proposed work will shed light on this process, which also has profound implications for general cell and molecular biology...
  58. GENETIC EPIDEMIOLOGY OF ELEVATED APOB LEVEL
    GAIL JARVIK; Fiscal Year: 1999
    ..Aim 5. To refine the position of the apolipoprotein B elevating level gene(s). Aim 6. Subsequent work to identify the locus if positive evidence of linkage to a strong candidate gene region is obtained. ..
  59. FISH OIL, LIPOPROTEINS AND ATHERIOGENESIS
    Dong Kim; Fiscal Year: 1990
    ..In the vitro studies we shall investigate and compare the effects of specific lipoprotein fractions on: (1) cell proliferation, (2) cell death and (3) uptake of lipid...
  60. MECHANISM OF PI-RELATED DYSLIPIDEMIA AND ATHEROSCLEROSIS
    Daniel Rader; Fiscal Year: 2004
    ..These studies will provide novel insights into the mechanisms of PI-associated dyslipidemia and atherosclerosis. ..
  61. LOW DENSITY LIPOPROTEIN AND INFLAMMATION
    Robert Terkeltaub; Fiscal Year: 1993
    ....
  62. APOLIPOPROTEIN E IN CHOLESTEROL TRANSPORT AND METABOLISM
    ROBERT PITAS; Fiscal Year: 1992
    ..Together, these studies will help elucidate the role of apo-E in normal nervous tissue and in nerve regeneration...
  63. METABOLIC REGULATION OF APOLIPOPROTEIN B MRNA EDITING
    Harold Smith; Fiscal Year: 2003
    ....
  64. ENTEROHEPATIC LIPID FLUX AND APOPROTEIN BIOSYNTHESIS.
    NICHOLAS DAVIDSON; Fiscal Year: 2009
    ..We will examine the hypothesis in the current application that there are other cytidine deaminases, related to apobec-1, with functions involving site-specific RNA interactions. ..
  65. INTESTINAL SPECIFIC APO B: ASSEMBLY AND PROCESSING
    VODEK SASAK; Fiscal Year: 1990
    ..This should contribute to the understanding of intestinal lipid metabolism and determination of metabolic defects in various lipid disorders...
  66. INSULIN ACTION IN THE LIVER
    John Amatruda; Fiscal Year: 1992
    ....
  67. MACROPHAGE CHYLOMICRON/B48 RECEPTOR, BINDING MECHANISMS
    William Bradley; Fiscal Year: 2004
    ..abstract_text> ..